Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001086136 | SCV000644383 | benign | Tuberous sclerosis 2 | 2024-01-22 | criteria provided, single submitter | clinical testing | |
Eurofins Ntd Llc |
RCV000592123 | SCV000708103 | uncertain significance | not provided | 2017-05-10 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001086136 | SCV002039689 | likely benign | Tuberous sclerosis 2 | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Sema4, |
RCV002257812 | SCV002533336 | benign | Hereditary cancer-predisposing syndrome | 2022-01-06 | criteria provided, single submitter | curation | |
Ambry Genetics | RCV002257812 | SCV002752224 | likely benign | Hereditary cancer-predisposing syndrome | 2015-12-02 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Ce |
RCV000592123 | SCV004133838 | likely benign | not provided | 2023-06-01 | criteria provided, single submitter | clinical testing | TSC2: BP4, BP7 |